The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > FDA Launching Pilot Program to Assess Vaccine Safety Reporting Capabilities

FDA Launching Pilot Program to Assess Vaccine Safety Reporting Capabilities

Posted 28 May 2014 | By Alexander Gaffney, RAC

FDA Launching Pilot Program to Assess Vaccine Safety Reporting Capabilities

The US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) is launching a pilot program intended to assess its capacity to receive reports of adverse events related to the use of vaccines.

At present, CBER—working in tandem with the Centers for Disease Control and Prevention (CDC)—receives vaccine-related adverse events electronically through its Vaccine Adverse Event Reporting System (VAERS), which accepts the International Conference on Harmonisation's (ICH) Individual Case Safety Reporting (ICSR) format.

According to FDA, its pilot project is meant to "evaluate" its current system, presumably to determine if any changes or improvements are necessary.

FDA said it also wants to assess the use of ICH's E2B(R3) specification, which it says is "intended to improve the inherent quality of the data, enabling improved handling and analysis of ICSR reports." The E2B(R3) standard was adopted by FDA for use in February 2014.

The pilot program is expected to last for three months, but may last longer on an "as needed" basis, FDA wrote. FDA is accepting no more than six industry participants to be involved with the program.

 

Federal Register Announcement

 

© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe